# HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China

> **NCT02743065** · — · UNKNOWN · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** HepaSphere with 50-75mg Doxorubicin

## Key facts

- **NCT ID:** NCT02743065
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743065, "HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02743065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*